Chardan Capital Decreases Earnings Estimates for CervoMed

CervoMed Inc. (NASDAQ:CRVO) – Equities researchers at Chardan Capital dropped their FY2025 EPS estimates for shares of CervoMed in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now forecasts that the company will earn ($2.68) per share for the year, down from their prior forecast of ($1.22). Chardan Capital currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The company had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $1.51 million. CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%.

Several other brokerages have also recently issued reports on CRVO. HC Wainwright cut CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. Roth Mkm boosted their price objective on shares of CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, March 18th. Morgan Stanley restated an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of CervoMed in a report on Wednesday. Finally, Jones Trading raised shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Thursday, March 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.50.

CervoMed Stock Performance

NASDAQ:CRVO opened at $8.50 on Thursday. The firm has a market capitalization of $73.98 million, a PE ratio of -4.19 and a beta of 1.84. CervoMed has a 52-week low of $1.80 and a 52-week high of $25.92. The stock has a 50-day simple moving average of $3.85 and a two-hundred day simple moving average of $7.69.

Hedge Funds Weigh In On CervoMed

Large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of CervoMed in the 4th quarter valued at about $26,000. DRW Securities LLC acquired a new stake in CervoMed during the fourth quarter worth about $30,000. Mariner LLC purchased a new stake in shares of CervoMed during the 4th quarter valued at approximately $30,000. BNP Paribas Financial Markets acquired a new position in shares of CervoMed in the 4th quarter valued at $32,000. Finally, JPMorgan Chase & Co. boosted its stake in CervoMed by 251.8% during the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after buying an additional 10,352 shares during the period. 25.15% of the stock is currently owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.